Vancouver, BC, February 14, 2019 – Orion Nutraceuticals Inc., (CSE: ORI) (the “Company” or “Orion”) is pleased to announce a non-brokered private placement of up to 2,400,000 units at a price of CAD$0.25 per unit.

Each unit will consist of one common share and one transferable common share purchase warrant. Each whole warrant will entitle the holder to acquire one additional common share in the capital of the Company for a period of 24 months following the closing of the private placement at a price of CAD$0.50 per warrant share. The warrants will have an acceleration provision such that if the closing price of the Company’s common shares on the CSE for 10 consecutive trading days is $0.70 or above (the “Acceleration Event”), the Company may give notice of the Acceleration Event and the warrant expiry date will be accelerated to a date that is 30 days from the date of the notice. The Company may give notice of the Acceleration Event by news release.

The private placement is subject to the approval of the CSE and the securities will be subject to a four-month hold period under securities laws. The Company intends to use the net proceeds from the private placement for general working capital and corporate purposes.

About Orion Nutraceuticals Inc.
Orion Nutraceuticals Inc. aims to set a new standard in cannabis life science by producing and developing innovative products with key strategic partners in the industry. Orion’s 99% held subsidiary, has submitted its application for an ACMPR license and is currently under review with Health Canada. Build out is expected to begin in Q1 2019, with completion of the 30,000 square foot facility expected by Q3 2019. FCM supplies pharmaceutical, nutritional, wellness, and cosmetic companies in legal markets worldwide with customized medical cannabis extracts, oils, and isolates at commercial scale. FCM also collaborates with clients on research & development, conducting evidence-based pre-clinical and clinical trials. Orion shares trade in Canada on the CSE under the symbol ORI.

On behalf of the Board of Directors,
Jonathan Fiteni, CEO
Orion Nutraceuticals Inc.
www.orionnutra.ca

Investor Relations | Robin Linden
1.604.609.6196 | investors@orionnutra.ca